{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epanova",
    "query": {
      "intervention": "Epanova"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 12,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Epanova&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T18:40:11.010Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01208961",
      "title": "Epanova® Compared to Lovaza® In a Pharmacokinetic, Single-dose, Evaluation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Severe Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Epanova (4 g) and Lovaza (4 g)",
          "type": "DRUG"
        },
        {
          "name": "Lovaza (4 g) and Epanova (4 g)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2010-09",
      "completion_date": "2010-11",
      "has_results": true,
      "last_update_posted_date": "2015-07-15",
      "last_synced_at": "2026-09-03T18:40:11.010Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01208961"
    },
    {
      "nct_id": "NCT01431690",
      "title": "Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat Meals",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "warfarin",
          "type": "DRUG"
        },
        {
          "name": "omefas",
          "type": "DRUG"
        },
        {
          "name": "omega-3-acid ethyl esters",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 52,
      "start_date": "2011-08",
      "completion_date": "2011-10",
      "has_results": false,
      "last_update_posted_date": "2015-04-24",
      "last_synced_at": "2026-09-03T18:40:11.010Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431690"
    },
    {
      "nct_id": "NCT02009865",
      "title": "Epanova® for Lowering Very High Triglycerides II (EVOLVE II)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Epanova",
          "type": "DRUG"
        },
        {
          "name": "Olive Oil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 379,
      "start_date": "2013-12-16",
      "completion_date": "2014-12-23",
      "has_results": true,
      "last_update_posted_date": "2019-09-10",
      "last_synced_at": "2026-09-03T18:40:11.010Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • St. Petersburg, Florida • Addison, Illinois + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Addison",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02009865"
    },
    {
      "nct_id": "NCT02859129",
      "title": "Study to Evaluate the 2-Way Interaction Between Multiple Doses of Epanova™ and a Single Dose of Rosuvastatin (Crestor®)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "rosuvastatin 40 mg tablet",
          "type": "DRUG"
        },
        {
          "name": "Epanova™ QD (2 x 1 g capsules)",
          "type": "DRUG"
        },
        {
          "name": "Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose",
          "type": "DRUG"
        },
        {
          "name": "Multiple (20) oral doses of 2 g Vascepa® every 12 hours",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 114,
      "start_date": "2013-09",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2016-08-17",
      "last_synced_at": "2026-09-03T18:40:11.010Z",
      "location_count": 1,
      "location_summary": "Neptune City, New Jersey",
      "locations": [
        {
          "city": "Neptune City",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859129"
    },
    {
      "nct_id": "NCT01408303",
      "title": "[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertriglyceridemia",
        "Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Olive oil, 4g",
          "type": "DRUG"
        },
        {
          "name": "omega-3-carboxylic acids, 2g",
          "type": "DRUG"
        },
        {
          "name": "omega-3-carboxylic acids, 4g",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 646,
      "start_date": "2011-08",
      "completion_date": "2012-06",
      "has_results": true,
      "last_update_posted_date": "2014-12-05",
      "last_synced_at": "2026-09-03T18:40:11.010Z",
      "location_count": 89,
      "location_summary": "Muscle Shoals, Alabama • Chandler, Arizona • Phoenix, Arizona + 78 more",
      "locations": [
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01408303"
    },
    {
      "nct_id": "NCT02189252",
      "title": "An Open-Label Crossover Study to Compare the Relative Bioavailability, Efficacy and Safety of Epanova® and Lovaza® in Men and Women With a History of Pancreatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Severe Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Epanova",
          "type": "DRUG"
        },
        {
          "name": "Lovaza",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 30,
      "start_date": "2014-10",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-06-20",
      "last_synced_at": "2026-09-03T18:40:11.010Z",
      "location_count": 3,
      "location_summary": "Kansas City, Kansas • Cincinnati, Ohio • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02189252"
    },
    {
      "nct_id": "NCT02104817",
      "title": "Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)"
      ],
      "interventions": [
        {
          "name": "Epanova® (omega-3 carboxylic acids)",
          "type": "DRUG"
        },
        {
          "name": "corn oil control",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 13078,
      "start_date": "2014-10-30",
      "completion_date": "2020-05-27",
      "has_results": true,
      "last_update_posted_date": "2021-08-17",
      "last_synced_at": "2026-09-03T18:40:11.010Z",
      "location_count": 229,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Muscle Shoals, Alabama + 183 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02104817"
    },
    {
      "nct_id": "NCT00074542",
      "title": "An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Crohn's Disease"
      ],
      "interventions": [
        {
          "name": "Epanova™ (Omega-3 Free Fatty Acids)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tillotts Pharma AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 364,
      "start_date": "2002-09",
      "completion_date": "2005-01",
      "has_results": false,
      "last_update_posted_date": "2007-02-21",
      "last_synced_at": "2026-09-03T18:40:11.010Z",
      "location_count": 10,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Urbana, Illinois + 6 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Urbana",
          "state": "Illinois"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00074542"
    },
    {
      "nct_id": "NCT01486433",
      "title": "The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Simvastatin",
          "type": "DRUG"
        },
        {
          "name": "acetylsalicylic acid (ASA)",
          "type": "DRUG"
        },
        {
          "name": "omefas",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 52,
      "start_date": "2011-11",
      "completion_date": "2012-03",
      "has_results": false,
      "last_update_posted_date": "2015-04-30",
      "last_synced_at": "2026-09-03T18:40:11.010Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01486433"
    },
    {
      "nct_id": "NCT02113163",
      "title": "PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Diabetes Mellitus, Non-Insulin-Dependent",
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "Metformin Eicosapentaenoate",
          "type": "DRUG"
        },
        {
          "name": "Metformin HCl and Vascepa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Thetis Pharmaceuticals LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 32,
      "start_date": "2014-03",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2022-05-02",
      "last_synced_at": "2026-09-03T18:40:11.010Z",
      "location_count": 1,
      "location_summary": "Baton Rouge, Louisiana",
      "locations": [
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02113163"
    }
  ]
}